Since the start of January, hospitals are required by CMS to post their charges for services in a machine-readable format, but if they don’t, there are no penalties for noncompliance.
Since the start of January, hospitals are required by CMS to post their charges for services in a machine-readable format, but if they don’t, there are no penalties for noncompliance.
In a press call with reporters to discuss the rollout of the new rule, which went into effect January 1, CMS Administrator Seema Verma said the agency is gathering comments from stakeholders about the implementation of the requirement. She emphasized that the change is part of the agency’s price transparency efforts, with the idea that third-party app developers would create tools to make the information understandable to consumers.
“Patients are a driving force to improve quality and value,” said Verma. Without price transparency, “they cannot seek out the highest quality service at the lowest cost.”
The prices that hospitals are required to post are the chargemaster prices, meaning the price that would be charged to someone without insurance. There is also no way for consumers to know what out-of-pocket costs would be after insurance, or in the case of Medicare, what CMS covers.
The rule is a minimum bar, meaning hospitals can go beyond it if they want to post more detailed, or user-friendly information, Verma said.
Observers have also noted that there is no requirement stating where on a hospital website the information should be posted, and that not all of them are easy to find. If a hospital does not post the charges, there is no current enforcement mechanism.
Verma would not state a timeline for when discussions with stakeholders regarding penalties and enforcement would conclude. CMS also does not know how many hospitals have complied. The rule does not currently affect community health centers, but that is something CMS is looking at, she said.
Verma said she thinks posting the prices will encourage competition, thus helping to bring healthcare prices down. “Price transparency is critical to making healthcare more affordable,” she said. She also thinks patients will have information to make more informed decisions.
So far, however, efforts to connect price transparency to the way patients seek healthcare services have not incorporated every possible factor. For instance, a study published in the June 2017 issue of The American Journal of Managed Care® found that, while patients were interested in price transparency information, there was a disconnect between their enthusiasm for the idea and their reported use of a well-known price transparency tool called Castlight. Barriers to using price information for choosing care included the importance of the idea of price shopping for care and factors such as provider loyalty.
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More